Advertisement
Screener

ASTRAZENECA PLC (AZN) Form 6-K: Report of foreign private issuer, 2022, Page 2

ASTRAZENECA PLC Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2022-03-01: Form 6-K; Period of report 2022-03-01; Description DIRECTOR/PDMR SHAREHOLDING; Document a2408d.htm.
  • 2022-03-01: Form 6-K; Period of report 2022-03-01; Description TOTAL VOTING RIGHTS; Document a1848d.htm.
  • 2022-03-01: Form 6-K; Period of report 2022-03-01; Description ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006; Document a1181d.htm.
  • 2022-02-23: Form 6-K; Period of report 2022-02-23; Description FILING OF FORM 20-F WITH SEC; Document a4744c.htm.
FiledFormPeriod of reportDescriptionDocument
2022-03-016-K2022-03-01DIRECTOR/PDMR SHAREHOLDINGa2408d.htm
2022-03-016-K2022-03-01TOTAL VOTING RIGHTSa1848d.htm
2022-03-016-K2022-03-01ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006a1181d.htm
2022-02-236-K2022-02-23FILING OF FORM 20-F WITH SECa4744c.htm
2022-02-226-K2022-02-22CHAIR SUCCESSION PLANNING UPDATE AND ANNUAL REPORTa3476c.htm
2022-02-226-K2022-02-22ENHERTU IMPROVES PFS AND OS IN HER2-LOW BCa2559c.htm
2022-02-166-K2022-02-16SAPHNELO APPROVED IN EU FOR SLEa8051b.htm
2022-02-156-K2022-02-15LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATEa6586b.htm
2022-02-116-K2022-02-11DIRECTOR/PDMR SHAREHOLDINGa4708b.htm
2022-02-106-K2022-02-10AZN: FULL YEAR AND Q4 2021 RESULTSa2250b.htm
2022-02-016-K2022-02-01TOTAL VOTING RIGHTSa3376a.htm
2022-01-196-K2022-01-19IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCERa8910y.htm
2022-01-196-K2022-01-19IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCCa8908y.htm
2022-01-186-K2022-01-18ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCERa6391y.htm
2022-01-076-K2022-01-07ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006a7559x.htm
2022-01-056-K2022-01-05TRANSFER OF RIGHTS TO EKLIRA, DUAKLIR COMPLETEDa4814x.htm
2022-01-046-K2022-01-04TOTAL VOTING RIGHTSa3628x.htm